Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

247
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
247
Global Climate Change01:50

Global Climate Change

28.8K
Throughout its ~4.5 billion year history, the Earth has experienced periods of warming and cooling. However, the current drastic increase in global temperatures is well outside of the Earth’s cyclic norms, and evidence for human-caused global climate change is compelling. Paleoclimatology, the study of ancient climate conditions, provides ample evidence for human-caused global climate change by comparing recent conditions with those in the past.
28.8K
Introduction to Global Positioning System01:30

Introduction to Global Positioning System

490
The Global Positioning System (GPS) revolutionized positioning on Earth, providing precise location data through satellite ranging. The GPS system was developed in 1978 by the U.S. Department of Defense  for military use, and it became available for civilian applications in 1983, transforming fields including navigation, fleet management, and time synchronization for telecommunications systems.GPS consists of satellites in medium Earth orbit, about 20,200 kilometers above the surface,...
490
Global Regulatory Systems01:28

Global Regulatory Systems

623
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
623
Errors in Global Positioning System01:26

Errors in Global Positioning System

347
Global Positioning System (GPS) technology has revolutionized navigation and positioning, but its accuracy is often compromised by various errors. These errors, stemming from environmental, satellite, and receiver-related factors, require careful mitigation to ensure reliable performance across applications.Atmospheric ErrorsGPS signals travel through the Earth’s ionosphere and troposphere, introducing delays which affect accuracy. The ionosphere is strongly influenced by charged particles,...
347
Field Application of Global Positioning System01:28

Field Application of Global Positioning System

327
The Global Positioning System (GPS) has become an indispensable tool in fieldwork, offering unparalleled precision and efficiency for surveying, navigation, and infrastructure development. By harnessing signals from a constellation of satellites, GPS receivers determine the location of objects with remarkable speed and accuracy, often completing calculations within a second.Advantages of Modern GPS TechnologyContemporary GPS receivers are designed to meet the practical demands of field...
327

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Lenacapavir: First Approval.

Drugs·2023
Same author

Leniolisib: First Approval.

Drugs·2023
Same author

Lenacapavir: First Approval.

Drugs·2022
Same author

Correction to: Ozanimod: A Review in Ulcerative Colitis.

Drugs·2022
Same author

Ozanimod: A Review in Ulcerative Colitis.

Drugs·2022
Same author

Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.

Paediatric drugs·2022
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Jan 22, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.5K

Volanesorsen: First Global Approval.

Julia Paik1, Sean Duggan2

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.

Drugs
|July 14, 2019
PubMed
Summary
This summary is machine-generated.

Volanesorsen is an antisense oligonucleotide approved in the EU for treating familial chylomicronemia syndrome (FCS). It inhibits apolipoprotein CIII (apoCIII) mRNA, offering a new option for patients with genetically confirmed FCS at high risk for pancreatitis.

More Related Videos

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K
Measuring Near Plasma Membrane and Global Intracellular Calcium Dynamics in Astrocytes
12:48

Measuring Near Plasma Membrane and Global Intracellular Calcium Dynamics in Astrocytes

Published on: April 26, 2009

13.5K

Related Experiment Videos

Last Updated: Jan 22, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.5K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K
Measuring Near Plasma Membrane and Global Intracellular Calcium Dynamics in Astrocytes
12:48

Measuring Near Plasma Membrane and Global Intracellular Calcium Dynamics in Astrocytes

Published on: April 26, 2009

13.5K

Area of Science:

  • Genetics and Molecular Biology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by severe hypertriglyceridemia.
  • Elevated levels of apolipoprotein CIII (apoCIII) play a crucial role in the pathophysiology of FCS.
  • Current treatment options for FCS are limited, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To summarize the development milestones of volanesorsen, an antisense oligonucleotide targeting apoCIII mRNA.
  • To highlight the regulatory approval of volanesorsen in the European Union for adult patients with FCS.
  • To review the clinical trial data supporting its efficacy and safety in FCS management.

Main Methods:

  • Development of volanesorsen, an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA.
  • Phase III clinical trials (APPROACH and COMPASS studies) evaluating volanesorsen in adult patients with FCS.
  • Analysis of clinical data for efficacy in reducing triglyceride levels and risk of pancreatitis.

Main Results:

  • Volanesorsen demonstrated significant reduction in triglyceride levels in patients with FCS.
  • Positive results from multinational Phase III studies supported its efficacy.
  • EU approval granted in May 2019 for adult patients with genetically confirmed FCS at high risk for pancreatitis.

Conclusions:

  • Volanesorsen represents a significant advancement in the treatment of FCS.
  • It provides a targeted therapeutic option by inhibiting apoCIII production.
  • The approval marks a milestone in managing this rare and severe hypertriglyceridemic disorder.